Certain Blood Separation and Cell Preparation Devices; Institution of Investigation, 8891-8892 [2019-04475]

Download as PDF Federal Register / Vol. 84, No. 48 / Tuesday, March 12, 2019 / Notices Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.12 of the Commission’s rules. By order of the Commission. Issued: March 7, 2019. William Bishop, Supervisory Hearings and Information Officer. [FR Doc. 2019–04474 Filed 3–11–19; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1099] Certain Graphics Processors and Products Containing the Same; Notice of Commission Determination Not To Review an Initial Determination Terminating the Investigation in Its Entirety Based on Settlement; Termination of the Investigation U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (‘‘ID’’) (Order No. 49) terminating the investigation in its entirety based on settlement. The investigation is terminated. SUMMARY: FOR FURTHER INFORMATION CONTACT: Robert Needham, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708–5468. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its internet server (https://www.usitc.gov). The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https:// edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on February 5, 2018, based on a complaint filed by ZiiLabs Inc., Ltd. of Hamilton, Bermuda (‘‘ZiiLabs’’). 83 FR VerDate Sep<11>2014 16:50 Mar 11, 2019 Jkt 247001 5141–42. The complaint alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain graphics processors and products containing the same that infringe certain claims of U.S. Patent Nos. 6,181,355; 6,900,800; 8,144,156; and 8,643,659. Id. at 5141. The Commission’s notice of investigation named as respondents ASUSTeK Computer Inc. of Taipei, Taiwan; ASUS Computer International of Freemont, California; EVGA Corporation of Brea, California; Gigabyte Technology Co., Ltd. of New Taipei City, Taiwan; G.B.T. Inc. of City of Industry, California; Micro-Star International Co., Ltd. of New Taipei City, Taiwan; MSI Computer Corp. of City of Industry, California; Nintendo Co., Ltd. of Kyoto, Japan; Nintendo of America, Inc. of Redmond, Washington; Nvidia Corporation of Santa Clara, California (‘‘Nvidia’’); PNY Technologies Inc. of Parsippany, New Jersey; Zotac International (MCO) Ltd. of Macau, China; and Zotac USA Inc. of Duarte, California. Id. at 5142. The Office of Unfair Import Investigations is not participating in this investigation. Id. On February 8, 2019, ZiiLabs filed an unopposed motion to terminate the investigation in its entirety based on several settlement agreements among ZiiLabs, Nvidia, and non-party RPX Corporation. The motion indicated that the agreements included a release for all respondents in the investigation. On February 12, 2019, the presiding administrative law judge issued the subject ID, granting the motion and terminating the investigation. No party petitioned for review of the ID. The Commission has determined not to review the subject ID. The investigation is terminated. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: March 6, 2019. Katherine Hiner, Acting Secretary to the Commission. [FR Doc. 2019–04405 Filed 3–11–19; 8:45 am] BILLING CODE 7020–02–P PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 8891 INTERNATIONAL TRADE COMMISSION [Inv. No. 337–TA–1147] Certain Blood Separation and Cell Preparation Devices; Institution of Investigation U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on January 30, 2019, under section 337 of the Tariff Act of 1930, as amended, on behalf of RegenLab USA LLC of New York, New York. An amended complaint was filed on February 15, 2019. The amended complaint alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain blood separation and cell preparation devices by reason of infringement of certain claims of U.S. Patent No. 10,064,894 (‘‘the ’894 patent’’). The amended complaint further alleges that an industry in the United States exists or in the process of being established as required by the applicable Federal Statute. The complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and a cease and desist order. ADDRESSES: The complaint, except for any confidential information contained therein, is available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Room 112, Washington, DC 20436, telephone (202) 205–2000. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205– 2000. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. FOR FURTHER INFORMATION CONTACT: The Office of Unfair Import Investigations, U.S. International Trade Commission, telephone (202) 205–2560. SUPPLEMENTARY INFORMATION: SUMMARY: E:\FR\FM\12MRN1.SGM 12MRN1 8892 Federal Register / Vol. 84, No. 48 / Tuesday, March 12, 2019 / Notices Authority: The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 and in section 210.10 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10 (2017). Scope of Investigation: Having considered the complaint, the U.S. International Trade Commission, on March 6, 2019, ordered that— (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain products identified in paragraph (2) by reason of infringement of one or more of claims 1–24 of the ’894 patent, and whether an industry in the United States exists or in the process of being established as required by subsection (a)(2) of section 337; (2) Pursuant to section 210.10(b)(1) of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10(b)(1), the plain language description of the accused products or category of accused products, which defines the scope of the investigation, is ‘‘blood separation and cell preparation devices that allow clinicians to collect a patient’s blood and separate platelet rich plasma from the blood, which is then used to treat the patient’’; (3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served: (a) The complainant is: RegenLab USA LLC, 575 Madison Avenue, Suite 1006, New York, NY 10022. (b) The respondent is the following entity alleged to be in violation of section 337, and is the party upon which the complaint is to be served: Estar Technologies, Ltd., 15 Hamerkava Street, Holon 5885111, Israel. Eclipse MedCorp, LLC, 5916 Stone Creek Drive, Suite 120, The Colony, TX 75056. (c) The Office of Unfair Import Investigations, U.S. International Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and (4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge. Responses to the complaint and the notice of investigation must be VerDate Sep<11>2014 16:50 Mar 11, 2019 Jkt 247001 submitted by the named respondent in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown. Failure of the respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent. By order of the Commission. Issued: March 7, 2019. William Bishop, Supervisory Hearings and Information Officer. [FR Doc. 2019–04475 Filed 3–11–19; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–595–596 and 731–TA–1401, 1403, 1405–1406 (Final)] Large Diameter Welded Pipe From Canada, Greece, Korea, and Turkey; Scheduling of the Final Phase of Antidumping and Countervailing Duty Investigations United States International Trade Commission. ACTION: Notice. AGENCY: DATES: March 6 2019. FOR FURTHER INFORMATION CONTACT: Lawrence Jones (202) 205–3358), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearingimpaired persons can obtain information on this matter by contacting the Commission’s TDD terminal on 202– 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (https:// www.usitc.gov). The public record for these investigations may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. SUPPLEMENTARY INFORMATION: Effective August 27, 2018, the Commission established a general schedule for the conduct of the final phase of its investigations on large diameter welded (LDW) pipe from Canada, China, Greece, India, Korea, and Turkey,1 following preliminary determinations by the U.S. Department of Commerce (‘‘Commerce’’) that certain benefits which constitute subsidies within the meaning of section 703 of the Act (19 U.S.C. 1671b) are being provided to manufacturers, producers, or exporters in China, India, Korea, and Turkey of large diameter welded (LDW) pipe, and that such products from Canada, China, Greece, India, Korea, and Turkey are being sold in the United States at less than fair value (LTFV) within the meaning of section 733 of the Act (19 U.S.C. 1673b).2 Notice of the scheduling of the final phase of the Commission’s investigations and of a public hearing held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register on September 6, 2018 (83 FR 45279). The hearing was held in Washington, DC, on November 6, 2018, and all persons who requested the opportunity were permitted to appear in person or by counsel. Following affirmative final determinations by Commerce regarding LTFV and subsidized imports of LDW pipe from China and India, the Commission issued its final determinations that an industry in the United States was materially injured by reason of LTFV and subsidized imports of LDW line pipe from India; that an industry in the United States is materially injured by reason of LTFV and subsidized imports of LDW structural pipe from China; and that an industry in the United States is threatened with material injury by reason of LTFV imports of LDW line pipe from China. Further, the Commission has terminated the countervailing duty investigation on 1 Large Diameter Welded Pipe From Canada, China, Greece, India, Korea, and Turkey; Scheduling of the Final Phase of Countervailing Duty and Antidumping Duty Investigations, 83 FR 45279, September 6, 2018. 2 See generally 83 FR 30690–30699, June 29, 2018, and 83 FR 43640–43656, August 27, 2018. E:\FR\FM\12MRN1.SGM 12MRN1

Agencies

[Federal Register Volume 84, Number 48 (Tuesday, March 12, 2019)]
[Notices]
[Pages 8891-8892]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-04475]


-----------------------------------------------------------------------

 INTERNATIONAL TRADE COMMISSION

[Inv. No. 337-TA-1147]


Certain Blood Separation and Cell Preparation Devices; 
Institution of Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that a complaint was filed with the 
U.S. International Trade Commission on January 30, 2019, under section 
337 of the Tariff Act of 1930, as amended, on behalf of RegenLab USA 
LLC of New York, New York. An amended complaint was filed on February 
15, 2019. The amended complaint alleges violations of section 337 based 
upon the importation into the United States, the sale for importation, 
and the sale within the United States after importation of certain 
blood separation and cell preparation devices by reason of infringement 
of certain claims of U.S. Patent No. 10,064,894 (``the '894 patent''). 
The amended complaint further alleges that an industry in the United 
States exists or in the process of being established as required by the 
applicable Federal Statute.
    The complainant requests that the Commission institute an 
investigation and, after the investigation, issue a limited exclusion 
order and a cease and desist order.

ADDRESSES: The complaint, except for any confidential information 
contained therein, is available for inspection during official business 
hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW, Room 112, Washington, 
DC 20436, telephone (202) 205-2000. Hearing impaired individuals are 
advised that information on this matter can be obtained by contacting 
the Commission's TDD terminal on (202) 205-1810. Persons with mobility 
impairments who will need special assistance in gaining access to the 
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be 
obtained by accessing its internet server at https://www.usitc.gov. The 
public record for this investigation may be viewed on the Commission's 
electronic docket (EDIS) at https://edis.usitc.gov.

FOR FURTHER INFORMATION CONTACT: The Office of Unfair Import 
Investigations, U.S. International Trade Commission, telephone (202) 
205-2560.

SUPPLEMENTARY INFORMATION: 

[[Page 8892]]

    Authority: The authority for institution of this investigation is 
contained in section 337 of the Tariff Act of 1930, as amended, 19 
U.S.C. 1337 and in section 210.10 of the Commission's Rules of Practice 
and Procedure, 19 CFR 210.10 (2017).
    Scope of Investigation: Having considered the complaint, the U.S. 
International Trade Commission, on March 6, 2019, ordered that--
    (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 
1930, as amended, an investigation be instituted to determine whether 
there is a violation of subsection (a)(1)(B) of section 337 in the 
importation into the United States, the sale for importation, or the 
sale within the United States after importation of certain products 
identified in paragraph (2) by reason of infringement of one or more of 
claims 1-24 of the '894 patent, and whether an industry in the United 
States exists or in the process of being established as required by 
subsection (a)(2) of section 337;
    (2) Pursuant to section 210.10(b)(1) of the Commission's Rules of 
Practice and Procedure, 19 CFR 210.10(b)(1), the plain language 
description of the accused products or category of accused products, 
which defines the scope of the investigation, is ``blood separation and 
cell preparation devices that allow clinicians to collect a patient's 
blood and separate platelet rich plasma from the blood, which is then 
used to treat the patient'';
    (3) For the purpose of the investigation so instituted, the 
following are hereby named as parties upon which this notice of 
investigation shall be served:
    (a) The complainant is:

RegenLab USA LLC, 575 Madison Avenue, Suite 1006, New York, NY 10022.
    (b) The respondent is the following entity alleged to be in 
violation of section 337, and is the party upon which the complaint is 
to be served:

Estar Technologies, Ltd., 15 Hamerkava Street, Holon 5885111, Israel.
Eclipse MedCorp, LLC, 5916 Stone Creek Drive, Suite 120, The Colony, TX 
75056.
    (c) The Office of Unfair Import Investigations, U.S. International 
Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and
    (4) For the investigation so instituted, the Chief Administrative 
Law Judge, U.S. International Trade Commission, shall designate the 
presiding Administrative Law Judge.
    Responses to the complaint and the notice of investigation must be 
submitted by the named respondent in accordance with section 210.13 of 
the Commission's Rules of Practice and Procedure, 19 CFR 210.13. 
Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be 
considered by the Commission if received not later than 20 days after 
the date of service by the Commission of the complaint and the notice 
of investigation. Extensions of time for submitting responses to the 
complaint and the notice of investigation will not be granted unless 
good cause therefor is shown.
    Failure of the respondent to file a timely response to each 
allegation in the complaint and in this notice may be deemed to 
constitute a waiver of the right to appear and contest the allegations 
of the complaint and this notice, and to authorize the administrative 
law judge and the Commission, without further notice to the respondent, 
to find the facts to be as alleged in the complaint and this notice and 
to enter an initial determination and a final determination containing 
such findings, and may result in the issuance of an exclusion order or 
a cease and desist order or both directed against the respondent.

    By order of the Commission.

    Issued: March 7, 2019.
William Bishop,
Supervisory Hearings and Information Officer.
[FR Doc. 2019-04475 Filed 3-11-19; 8:45 am]
 BILLING CODE 7020-02-P